Dendritic Cell

A dendritic cell (DC) is a bone-marrow-derived hematopoietic leukocyte equipped with dynamic, stellate cytoplasmic projections (dendrites, from the Greek dendron for "tree") that functions as the vertebrate immune system's most potent professional antigen-presenting cell (APC). Discovered and purified from murine spleen suspensions in 1973 by Ralph M. Steinman and Zanvil A. Cohn at Rockefeller University—a discovery for which Steinman was awarded the 2011 Nobel Prize in Physiology or Medicine—dendritic cells form the indispensable cellular bridge linking innate pathogen sensing to the clonal initiation of adaptive T-cell and B-cell immunology.

Whereas tissue-resident macrophages specialize in local pathogen clearance and B lymphocytes present soluble cognate antigens primarily to already-primed helper T cells, dendritic cells possess the unique capacity to activate immunologically naive CD4⁺ and CD8⁺ T lymphocytes (which circulate through secondary lymphoid organs at clonal precursor frequencies of 1 in 10⁵ to 1 in 10⁶). Distributed as an immature sentinel network across peripheral barrier tissues (skin epidermis, respiratory and gastrointestinal mucosae, and interstitial parenchyma), dendritic cells continuously sample their microenvironment via phagocytosis and macropinocytosis; upon detecting microbial pathogen-associated molecular patterns (PAMPs) or endogenous damage-associated molecular patterns (DAMPs), they undergo a coordinated maturation program, migrate via afferent lymphatics to draining lymph nodes, and deliver the three molecular signals required for T-cell activation and differentiation.

Hematopoietic Specification and FMS-Like Tyrosine Kinase 3 Ligand (FLT3L)

Most steady-state dendritic cells arise in the bone marrow from multipotent hematopoietic stem cells via a sequential hierarchy of myeloid/dendritic progenitors—progressing from the macrophage and dendritic cell progenitor (MDP) to the common dendritic cell progenitor (CDP)—under the non-redundant instructive control of the cytokine FMS-like tyrosine kinase 3 ligand (FLT3L) signaling through the receptor tyrosine kinase FLT3 (CD135). Single-cell transcriptomics and lineage-tracing studies classify human and murine dendritic cells into four principal developmental and functional subsets:

1. Conventional Type 1 Dendritic Cells (cDC1): Specified by the lineage-defining transcription factors IRF8 (Interferon Regulatory Factor 8), BATF3, and ID2, cDC1s express the surface chemokine receptor XCR1, the C-type lectin CLEC9A (DNGR-1) (which binds F-actin exposed by necrotic cells), and CD141 (BDCA-3) in humans (or CD8α⁺ in lymphoid tissues and CD103⁺ in non-lymphoid peripheral tissues in mice). cDC1s are uniquely specialized for antigen cross-presentation on MHC Class I to prime cytotoxic CD8⁺ T lymphocytes (CTLs) and secrete interleukin-12 (IL-12) to polarize type 1 helper (T_H1) and natural killer responses against intracellular pathogens and tumors.
2. Conventional Type 2 Dendritic Cells (cDC2): Dependent on the transcription factors IRF4, KLF4, and ZEB2, cDC2s represent the most abundant conventional DC subset in human blood and tissues, characterized by expression of CD1c (BDCA-1), SIRPα (CD172a), and CD11b. Equipped with a broad repertoire of cytosolic and surface pattern-recognition receptors (including TLR2, TLR4, TLR5, TLR8, and Dectin-1), cDC2s excel at processing exogenous antigens onto MHC Class II molecules to prime naive CD4⁺ T cells into T_H2 (anti-helminth), T_H17 (extracellular bacterial and fungal clearance via IL-23 and IL-6), and follicular helper (T_FH) subsets.
3. Plasmacytoid Dendritic Cells (pDC): Specified by the basic helix-loop-helix transcription factor TCF4 (E2-2) and lacking myeloid markers CD11c/CD11b in humans (expressing CD123 [IL-3Rα], CD303 [BDCA-2], and CD304 [BDCA-4]), pDCs circulate in blood and lymphoid tissues with a spherical, secretory plasma-cell-like morphology containing abundant rough endoplasmic reticulum. Upon sensing viral single-stranded RNA via endosomal TLR7 or unmethylated CpG DNA via TLR9 (Toll-like receptors), pDCs activate MyD88–IRF7 signaling to secrete massive quantities of Type I interferons (IFN-α and IFN-β)—producing up to 1–2 picograms per cell (100- to 1,000-fold more than any other blood leukocyte) within 12 hours of viral encounter.
4. Langerhans Cells (LCs) and Monocyte-Derived Dendritic Cells (moDCs): Langerhans cells reside in the suprabasal stratified squamous epidermis of the skin; ontogenetically related to fetal yolk-sac/liver macrophages, they self-renew in situ under TGF-β1 and IL-34 signaling and contain characteristic tennis-racket-shaped pentalaminar cytoplasmic organelles called Birbeck granules assembled by the C-type lectin langerin (CD207). During acute inflammation, Ly6C^hi (CD14⁺) blood monocytes extravasate into infected tissues and differentiate under GM-CSF into inflammatory monocyte-derived DCs (moDCs).

Immature Antigen Capture vs. Mature Antigen Presentation

The physiological efficacy of conventional dendritic cells depends on a regulated developmental transition between two mutually exclusive functional states:

• Immature Sentinel State (Peripheral Tissues): Immature DCs stationed in peripheral tissues exhibit high endocytic activity, continuously internalizing extracellular fluid via constitutive macropinocytosis, receptor-mediated endocytosis (via C-type lectins such as DC-SIGN [CD209], mannose receptor CD206, and DEC-205), and phagocytosis of apoptotic bodies and microbes. In this immature state, MHC Class II molecules turn over rapidly via MARCH1 E3 ubiquitin-ligase-mediated ubiquitination and reside predominantly inside late endosomal MHC Class II compartments (MIICs), while cell-surface expression of costimulatory molecules (CD80/B7-1, CD86/B7-2, CD40) is low.
• PAMP/DAMP-Triggered Maturation and CCR7 Chemotaxis: Engagement of pattern-recognition receptors—such as Toll-like receptors (TLRs), cytosolic cGAS–STING, RIG-I/MDA5, or C-type lectins—triggers a profound metabolic and transcriptional switch (including a rapid shift to aerobic glycolysis to supply citrate for membrane synthesis). Within hours, the maturing DC downregulates macropinocytosis and phagocytosis and downregulates MARCH1, halting new antigen capture and locking existing peptide–MHC Class II complexes onto the plasma membrane (extending MHC-II half-life from ~10 hours to >100 hours). Simultaneously, the cell downregulates inflammatory tissue-homing chemokine receptors (CCR1, CCR2, CCR5, CCR6) and strongly upregulates CCR7, the G-protein-coupled receptor for the homeostatic chemokines CCL19 and CCL21 secreted by lymphatic endothelial cells and fibroblastic reticular cells in the paracortical T-cell zones of draining lymph nodes.

Signal 1, Signal 2, Signal 3, and Immunological Tolerance

Once inside the lymph node paracortex (or splenic periarteriolar lymphoid sheath), a mature dendritic cell extends long veiled dendrites that scan up to 500 to 5,000 naive T cells per hour. Productive activation and clonal expansion of a naive T cell across the immunological synapse requires the coordinated delivery of three distinct signals:

1. Signal 1 (Antigen-Specific TCR Engagement): The T-cell receptor (TCR–CD3 complex) and coreceptor (CD4 or CD8) recognize a linear antigenic peptide bound in the groove of an MHC Class II molecule (13–25 amino acids, generated by endolysosomal cathepsin S/L proteolysis and loaded via HLA-DM displacement of the invariant chain CLIP fragment) or an MHC Class I molecule (8–10 amino acids, generated by the immunoproteasome and imported into the endoplasmic reticulum via the TAP1/TAP2 transporter).
2. Signal 2 (Costimulation): Surface CD80 (B7-1) and CD86 (B7-2) on the mature DC bind the activating receptor CD28 on the naive T cell, activating PI3K–Akt and NF-κB pathways that drive interleukin-2 (IL-2) transcription and anti-apoptotic Bcl-x_L expression. Reciprocally, CD40L (CD154) upregulated on the activated CD4⁺ T cell engages CD40 on the DC ("DC licensing"), upregulating CD70 and 4-1BBL to license robust CD8⁺ CTL memory generation. Crucially, if an immature steady-state DC presents a self-peptide (Signal 1) in the absence of Signal 2 (no PAMP encounter), the T cell undergoes clonal anergy, deletion, or conversion into an immunosuppressive FOXP3⁺ regulatory T cell (T_reg)—establishing peripheral tolerance.
3. Signal 3 (Polarizing Cytokines): The specific cytokine milieu secreted by the mature DC instructs the lineage fate of the proliferating CD4⁺ T cell: IL-12 drives T-bet⁺ T_H1 differentiation; IL-6, IL-23, and TGF-β drive RORγt⁺ T_H17 differentiation; IL-10 and TGF-β + retinoic acid induce FOXP3⁺ T_reg cells.

Antigen Cross-Presentation by cDC1s

Under classical MHC rules, endogenous cytosolic proteins are presented on MHC Class I to CD8⁺ T cells, whereas exogenous phagocytosed proteins are presented on MHC Class II to CD4⁺ T cells. However, if a virus does not directly infect dendritic cells—or if a tumor arises in non-hematopoietic epithelial cells—naive CD8⁺ T cells could never be primed without antigen cross-presentation, discovered by Michael Bevan in 1976. cDC1s accomplish cross-presentation by recruiting the NADPH oxidase NOX2 and inhibiting V-ATPase assembly via Rab27a and SEC22B on phagosomes, maintaining a mildly alkaline phagosomal pH (~7.2–7.5) that prevents destructive over-digestion of antigens by acidic cathepsins. Intact or partially degraded polypeptide antigens are then exported from the phagosome into the cytosol (via ER-associated degradation translocons or pore-forming perforin-2 / Sec61 pathways), cleaved by the cytosolic proteasome, and loaded onto MHC Class I via TAP1/TAP2.

Why can't macrophages or B cells substitute for dendritic cells in priming a primary T-cell response?

Although macrophages, B cells, and dendritic cells all express MHC Class II and are classified as professional APCs, tissue macrophages remain fixed at sites of infection and acidify their phagolysosomes rapidly to pH ~4.5 to destroy pathogens completely rather than preserving antigenic peptides, while naive B cells cannot efficiently internalize non-cognate particulate antigens. Only dendritic cells combine constitutive peripheral antigen sampling, PAMP-induced CCR7 lymphatic migration into T-cell paracortical zones, phagosomal pH control for cross-presentation, and high-density CD80/CD86 expression needed to activate rare naive T cells.

How do dendritic cells maintain peripheral self-tolerance in the absence of infection?

In healthy, uninfected tissues, dying host cells undergo apoptosis and are phagocytosed by immature steady-state dendritic cells without releasing PAMPs or inflammatory DAMPs. These "tolerogenic" semi-mature DCs migrate constitutively to draining lymph nodes via CCR7 and present self-peptides on MHC Class I and II (Signal 1) while expressing very low levels of costimulatory CD80/CD86 (lacking Signal 2) and high levels of coinhibitory PD-L1, IDO1 (indoleamine 2,3-dioxygenase), and retinaldehyde dehydrogenase (generating retinoic acid + TGF-β), which either deletes autoreactive T cells or converts them into protective FOXP3⁺ T_reg cells.

Why are cDC1 dendritic cells essential for the efficacy of cancer immunotherapy (immune checkpoint blockade)?

Tumors evade the immune system in part because cancer cells are non-professional APCs lacking CD80/CD86 costimulation. Intratumoral BATF3-dependent cDC1s capture necrotic tumor debris via CLEC9A, preserve tumor neoantigens in alkaline phagosomes, migrate to tumor-draining lymph nodes to cross-present neoantigens on MHC Class I to naive CD8⁺ T cells, and secrete CXCL9 and CXCL10 within the tumor microenvironment to recruit effector CXCR3⁺ CD8⁺ T cells that are rejuvenated by anti-PD-1 / anti-CTLA-4 checkpoint blockade.

1. Steinman, R. M., & Cohn, Z. A. (1973). "Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution." Journal of Experimental Medicine, 137(5), 1142–1162. https://doi.org/10.1084/jem.137.5.1142
2. Banchereau, J., & Steinman, R. M. (1998). "Dendritic cells and the control of immunity." Nature, 392(6673), 245–252. https://doi.org/10.1038/32588
3. Merad, M., Sathe, P., Helft, J., Miller, J., & Mortha, A. (2013). "The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting." Annual Review of Immunology, 31, 563–604. https://doi.org/10.1146/annurev-immunol-020711-074950
4. Joffre, O. P., Segura, E., Savina, A., & Amigorena, S. (2012). "Cross-presentation by dendritic cells." Nature Reviews Immunology, 12(8), 557–569. https://doi.org/10.1038/nri3254